Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Opens in a new tab or window Generalized myasthenia gravis (gMG ... "Certain medications, including beta-blockers, calcium channel blockers, aminoglycoside and fluoroquinolone antibiotics ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis ... in ...

Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...

Decreased AChR-Ab titers correlated with improved myasthenia gravis symptoms, especially in ADL scores, within the first 3 months of treatment. The study found no baseline correlation between AChR ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor ...

THE occurrence of thyrotoxicosis in patients with myasthenia gravis is not rare, over 90 such cases having been reported since the turn of the century. 1,2 Various estimates place the incidence of ...

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profileof VYVGART and VYVGART HytrulogMG patients on VYVGART ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...